Abstract
Background
To evaluate early urinary (GU) and gastrointestinal (GI) adverse events (AEs) after
two or one fraction of high-dose rate brachytherapy (HDR-BT) in advanced prostate
cancer.
Patients and methods
165 patients were treated with 2 × 13 Gy (n = 115), or a single dose of 19 Gy (n = 24) or 20 Gy (n = 26) HDR-BT. Early AEs were assessed using the RTOG scoring system and the International
Prostate Symptom Score (IPSS).
Results
Week-2 prevalence of severe IPSS symptoms was higher after 20 Gy than after 26 or 19 Gy but by 12 weeks all groups were at pre-treatment levels or less. Grade-3 GU toxicity was observed
⩽9% of patients. No Grade 4 GU and no Grade 3 or 4 GI complications were observed.
However, there was a significant increase in catheter use in the first 12 weeks after implant after 19 and 20 Gy compared with 2 × 13 Gy.
Conclusion
Single dose HDR-BT is feasible with acceptable levels of acute complications; tolerance
may have been reached with the single 19 Gy schedule.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Radiotherapy and OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.Int J Radiat Oncol Biol Phys. 2012; 83: 927-932
- A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.Int J Radiat Oncol Biol Phys. 2008; 72: 441-446
- High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.Int J Radiat Oncol Biol Phys. 2011; 81: 1286-1292
- High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.Int J Radiat Oncol Biol Phys. 2012; 82: 1376-1384
- High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.Am J Clin Oncol. 2010; 33: 481-488
- High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.Int J Radiat Oncol Biol Phys. 2013; 85: 543-548
- Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions.Int J Radiat Oncol Biol Phys. 2011; 80: 469-475
- GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update.Radiother Oncol. 2013; 197: 325-332
- Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer.Radiother Oncol. 2009; 93: 253-258
- High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial.Int J Radiat Oncol Biol Phys. 2012; 82: 1889-1896
- Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.Brachytherapy. 2009; 8: 45-51
- High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results.Brachytherapy. 2012; 11: 105-110
- High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer.Radiother Oncol. 2006; 80: 62-68
- High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.Int J Radiat Oncol Biol Phys. 2012; 85: 672-678
- American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.Brachytherapy. 2012; 11: 6-19
- Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.Radiother Oncol. 2007; 83: 3-10
- Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) >/=180 Gy.Int J Radiat Oncol Biol Phys. 2010; 78: 422-427
- Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.Int J Radiat Oncol Biol Phys. 2003; 57: 645-653
- A dose-response study for I-125 prostate implants.Int J Radiat Oncol Biol Phys. 1998; 41: 101-108
Article info
Publication history
Published online: November 13, 2013
Received in revised form:
August 11,
2013
Received:
February 20,
2013
Identification
Copyright
© 2013 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
